Adlai Nortye Ltd. reported unaudited first-half 2026 financial results and operational updates for the period ended June 30, 2026. The company raised $290 million through two private placement equity financings completed in February ($140 million) and April ($150 million). Cash and short-term investments increased to US$231.9 million from US$8.1 million at year-end 2025. Revenue rose to US$13.1 million, driven by license agreement milestones with Jiangsu Aosaikang Pharmaceutical Co., Ltd., while net loss narrowed by 70.9% to US$5.3 million. R&D expenses decreased slightly to US$14.6 million. Clinically, the company initiated enrollment in both once-daily and intermittent once-weekly arms of its global Phase I trial for pan-RAS(ON) inhibitor AN9025 and received regulatory approval in Australia for a Phase I trial of ADC AN4035. Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on developing innovative cancer therapies.
